
Randall L. Beane
Examiner (ID: 15201, Phone: (571)270-3457 , Office: P/1675 )
| Most Active Art Unit | 1654 |
| Art Unit(s) | 1654, 1675 |
| Total Applications | 606 |
| Issued Applications | 172 |
| Pending Applications | 105 |
| Abandoned Applications | 346 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17290984
[patent_doc_number] => 20210386823
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => THERAPEUTIC AGENT FOR CARTILAGE DISORDER
[patent_app_type] => utility
[patent_app_number] => 17/287636
[patent_app_country] => US
[patent_app_date] => 2019-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4231
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287636
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/287636 | THERAPEUTIC AGENT FOR CARTILAGE DISORDER | Oct 24, 2019 | Pending |
Array
(
[id] => 17297911
[patent_doc_number] => 20210393750
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/287952
[patent_app_country] => US
[patent_app_date] => 2019-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21229
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -350
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287952
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/287952 | INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF | Oct 23, 2019 | Abandoned |
Array
(
[id] => 17385623
[patent_doc_number] => 20220033475
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION
[patent_app_type] => utility
[patent_app_number] => 17/279961
[patent_app_country] => US
[patent_app_date] => 2019-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9156
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279961
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/279961 | Compositions and methods for modulating Factor VIII function | Oct 22, 2019 | Issued |
Array
(
[id] => 17297896
[patent_doc_number] => 20210393735
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING TEICOPLANIN
[patent_app_type] => utility
[patent_app_number] => 17/287390
[patent_app_country] => US
[patent_app_date] => 2019-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4950
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287390
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/287390 | PHARMACEUTICAL COMPOSITION COMPRISING TEICOPLANIN | Oct 19, 2019 | Abandoned |
Array
(
[id] => 17154955
[patent_doc_number] => 20210316006
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => PYRROLOBENZODIAZEPINE CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/285811
[patent_app_country] => US
[patent_app_date] => 2019-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20312
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285811
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/285811 | PYRROLOBENZODIAZEPINE CONJUGATES | Oct 17, 2019 | Abandoned |
Array
(
[id] => 19112774
[patent_doc_number] => 20240124524
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => Agonist of Tacr2
[patent_app_type] => utility
[patent_app_number] => 17/768525
[patent_app_country] => US
[patent_app_date] => 2019-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15196
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768525
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/768525 | Agonist of Tacr2 | Oct 16, 2019 | Pending |
Array
(
[id] => 17198686
[patent_doc_number] => 20210338780
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA
[patent_app_type] => utility
[patent_app_number] => 17/285039
[patent_app_country] => US
[patent_app_date] => 2019-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21637
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -86
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285039
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/285039 | AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA | Oct 14, 2019 | Pending |
Array
(
[id] => 17356786
[patent_doc_number] => 20220017582
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, COMPRISING AEG-1 S298D AS ACTIVE INGREDIENT
[patent_app_type] => utility
[patent_app_number] => 17/291616
[patent_app_country] => US
[patent_app_date] => 2019-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3839
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291616
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/291616 | Composition for preventing or treating Parkinson's disease, comprising AEG-1 S298D as active ingredient | Oct 9, 2019 | Issued |
Array
(
[id] => 15646659
[patent_doc_number] => 20200085859
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => THERAPEUTIC POLYMER GEL SYSTEM TO PROMOTE HEALING AND PREVENT FIBROSIS AT A WOUND OR SURGICAL SITE
[patent_app_type] => utility
[patent_app_number] => 16/596312
[patent_app_country] => US
[patent_app_date] => 2019-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16596312
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/596312 | THERAPEUTIC POLYMER GEL SYSTEM TO PROMOTE HEALING AND PREVENT FIBROSIS AT A WOUND OR SURGICAL SITE | Oct 7, 2019 | Abandoned |
Array
(
[id] => 15740589
[patent_doc_number] => 20200109182
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-09
[patent_title] => GLP-1 ANALOG FUSION PROTEIN AND PREPARATION METHOD AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/596430
[patent_app_country] => US
[patent_app_date] => 2019-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16596430
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/596430 | GLP-1 ANALOG FUSION PROTEIN AND PREPARATION METHOD AND APPLICATION THEREOF | Oct 7, 2019 | Abandoned |
Array
(
[id] => 16976192
[patent_doc_number] => 20210220429
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ULCER OR FISTULA IN INTESTINAL TRACT
[patent_app_type] => utility
[patent_app_number] => 17/250969
[patent_app_country] => US
[patent_app_date] => 2019-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4656
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17250969
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/250969 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ULCER OR FISTULA IN INTESTINAL TRACT | Oct 3, 2019 | Abandoned |
Array
(
[id] => 17383958
[patent_doc_number] => 20220031810
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
[patent_app_type] => utility
[patent_app_number] => 17/279691
[patent_app_country] => US
[patent_app_date] => 2019-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9739
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279691
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/279691 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | Sep 26, 2019 | Pending |
Array
(
[id] => 17334458
[patent_doc_number] => 20220000789
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 17/280802
[patent_app_country] => US
[patent_app_date] => 2019-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55367
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280802
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/280802 | IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS | Sep 26, 2019 | Pending |
Array
(
[id] => 17828247
[patent_doc_number] => 20220265551
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
[patent_app_type] => utility
[patent_app_number] => 17/276252
[patent_app_country] => US
[patent_app_date] => 2019-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15067
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276252
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/276252 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | Sep 26, 2019 | Pending |
Array
(
[id] => 17200105
[patent_doc_number] => 20210340200
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => CD40L ANTAGONIST AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/279772
[patent_app_country] => US
[patent_app_date] => 2019-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14972
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -113
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279772
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/279772 | CD40L ANTAGONIST AND USES THEREOF | Sep 24, 2019 | Abandoned |
Array
(
[id] => 17183922
[patent_doc_number] => 20210330807
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => NOVEL HYDROGEL CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/280738
[patent_app_country] => US
[patent_app_date] => 2019-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43420
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 533
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280738
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/280738 | NOVEL HYDROGEL CONJUGATES | Sep 24, 2019 | Abandoned |
Array
(
[id] => 17334653
[patent_doc_number] => 20220000984
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => GLP1-FC FUSION PROTEIN AND CONJUGATE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/279174
[patent_app_country] => US
[patent_app_date] => 2019-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13895
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279174
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/279174 | GLP1-FC FUSION PROTEIN AND CONJUGATE THEREOF | Sep 24, 2019 | Abandoned |
Array
(
[id] => 17790278
[patent_doc_number] => 20220249369
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => BIOLOGICAL BITS AS COMPUTABLE ELEMENTS WITHIN LIVING SYSTEMS
[patent_app_type] => utility
[patent_app_number] => 17/276711
[patent_app_country] => US
[patent_app_date] => 2019-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276711
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/276711 | BIOLOGICAL BITS AS COMPUTABLE ELEMENTS WITHIN LIVING SYSTEMS | Sep 18, 2019 | Pending |
Array
(
[id] => 17399579
[patent_doc_number] => 20220041669
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => METHODS OF TREATING OR PREVENTING CONDITIONS OF DENDRITIC AND NEURAL SPINE DEFECTS
[patent_app_type] => utility
[patent_app_number] => 17/277676
[patent_app_country] => US
[patent_app_date] => 2019-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18469
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277676
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/277676 | METHODS OF TREATING OR PREVENTING CONDITIONS OF DENDRITIC AND NEURAL SPINE DEFECTS | Sep 17, 2019 | Pending |
Array
(
[id] => 15324117
[patent_doc_number] => 20200002388
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-02
[patent_title] => Mating Factor Alpha Pro-Peptide Variants
[patent_app_type] => utility
[patent_app_number] => 16/573586
[patent_app_country] => US
[patent_app_date] => 2019-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9171
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573586
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/573586 | Mating Factor Alpha Pro-Peptide Variants | Sep 16, 2019 | Abandoned |